Whilst at Lilly’s Erl Wood at 50 celebration event, we sat down with Dan Skovronsky (Lilly, UK). In this interview, Dan talks about Lilly’s commitment to Alzheimer’s disease and the next steps in tackling the disease.
Daniel Skovronsky is Senior Vice President, Clinical and Product Development at Lilly, with responsibility for developing the Lilly pipeline of molecules and speeding innovative medicines to patients. Prior to this role he served as Vice President, Tailored Therapeutics. Dr Skovronsky also serves as Chairman of Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly and Company). Dr Skovronsky joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals.
This content has been financially supported by Lilly.